Ultra-Rapid Lispro results in accelerated insulin lispro absorption and faster early insulin action in comparison with Humalog(®) in Japanese patients with type 1 diabetes

What Was Tested

The paper reports a study of Insulin Lispro, published as a randomized controlled trial.

Ultra-rapid lispro (URLi) is a novel ultra-rapid mealtime insulin.

Who Took Part

The study group was 31 patients.

The age groups tagged for this paper are adults, both men and women.

This was a phase I, single center, randomized, patient- and investigator-blind, two-period, cross-over study.

How the Study Was Run

In design terms this was a randomized and crossover study.

Random assignment meant chance, not the researchers, decided who got Insulin Lispro and who got the comparison, which limits bias.

In the crossover set-up each of the patients took both Insulin Lispro and the comparison in turn, acting as their own control.

The glucodynamic endpoints were the time to early half-maximal glucose infusion rate before time to maximum glucose infusion rate, and the time to onset of insulin action.

What Was Measured

Topics PubMed links to this paper include Asian People, Diabetes Mellitus, Type 1, Glucose, Glucose Clamp Technique, Insulin, Insulin Lispro and Japan.

The authors tagged it with the keywords Japanese and Type 1 diabetes mellitus.

What This Means in Plain Language

The paper is a randomized and crossover study of Insulin Lispro in 31 patients.

With fewer than 40 people, it is a small study, so it is better read as an early signal for further research than as a settled answer.

Results are reported in around 7 sentences of the abstract; we leave them to the paper itself rather than summarise them.

The publication is from 2020 (Journal of diabetes investigation), a journal based in Japan.

More context: the Insulin Lispro compound page, all human trials.